Mark Rozenbaum
Mark Rozenbaum
Verified email at
Cited by
Cited by
Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 …
MH Rozenbaum, EAM Sanders, AJ van Hoek, AGSC Jansen, ...
Bmj 340, c2509, 2010
The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis
MH Rozenbaum, P Pechlivanoglou, TS Van Der Werf, JR Lo-Ten-Foe, ...
European journal of clinical microbiology & infectious diseases 32 (3), 305-316, 2013
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
IMCM de Kok, M van Ballegooijen, JDF Habbema
Journal of the National Cancer Institute 101 (15), 1083-1092, 2009
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis
MH Rozenbaum, MJJ Mangen, SM Huijts, TS van der Werf, MJ Postma
Vaccine 33 (28), 3193-3199, 2015
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
MJJ Mangen, MH Rozenbaum, SM Huijts, CH van Werkhoven, ...
European Respiratory Journal 46 (5), 1407-1416, 2015
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes
S Vegter, C Boersma, M Rozenbaum, B Wilffert, GJ Navis, MJ Postma
Pharmacoeconomics 26 (7), 569-587, 2008
Stem cell-related cardiac gene expression early after murine myocardial infarction
S Vandervelde, MJA van Luyn, MH Rozenbaum, AH Petersen, RA Tio, ...
Cardiovascular research 73 (4), 783-793, 2007
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
MH Rozenbaum, AJ van Hoek, D Fleming, CL Trotter, E Miller, ...
Bmj 345, e6879, 2012
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses
TA Westra, MH Rozenbaum, RM Rogoza, HW Nijman, T Daemen, ...
Journal of Infectious Diseases 204 (3), 377-384, 2011
Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged≥ 65 years in the Netherlands
MH Rozenbaum, E Hak, TS van der Werf, MJ Postma
Clinical therapeutics 32 (8), 1517-1532, 2010
Cost–effectiveness of varicella vaccination programs: an update of the literature
MH Rozenbaum, AJ Van Hoek, S Vegter, MJ Postma, Chant, Rawson, ...
Expert review of vaccines 7 (6), 753-782, 2008
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
MJ Postma, M Jit, MH Rozenbaum, B Standaert, HA Tu, RCW Hutubessy
BMC medicine 9 (1), 84, 2011
Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations
S Vegter, MH Rozenbaum, R Postema, K Tolley, MJ Postma
Clinical therapeutics 32 (9), 1651-1661, 2010
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
MH Rozenbaum, MJJ Mangen, C Giaquinto, JC Wilschut, E Hak, ...
BMC Public Health 11 (1), 462, 2011
Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination
MH Rozenbaum, C Boersma, MJ Postma, E Hak
Expert review of vaccines 10 (2), 187-199, 2011
Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar®)
MH Rozenbaum, AJ Van Hoek, E Hak, MJ Postma
Vaccine 28 (12), 2367-2369, 2010
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands
MJ Meijboom, MH Rozenbaum, A Benedictus, W Luytjes, MCJ Kneyber, ...
Vaccine 30 (31), 4691-4700, 2012
On discounting of health gains from human papillomavirus vaccination: effects of different approaches
TA Westra, M Parouty, WB Brouwer, PH Beutels, RM Rogoza, ...
Value in Health 15 (3), 562-567, 2012
Economic evaluations of rotavirus immunization for developing countries: a review of the literature
HAT Tu, HJ Woerdenbag, S Kane, MH Rozenbaum, SC Li, MJ Postma
Expert review of vaccines 10 (7), 1037-1051, 2011
Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
AT Urbanus, M van Keep, AA Matser, MH Rozenbaum, CJ Weegink, ...
PLoS One 8 (8), e70319, 2013
The system can't perform the operation now. Try again later.
Articles 1–20